Does Medicare cover Zepbound?

Short answer

Medicare covers Zepbound only when it is prescribed for an FDA-approved indication other than weight loss. Since December 2024, that means moderate-to-severe obstructive sleep apnea in adults with obesity (BMI ≥30). Medicare does not cover Zepbound for weight loss alone. Cost-sharing depends on the specific Part D plan or Medicare Advantage prescription drug plan.

The core rule: Medicare cannot cover weight-loss drugs

Under a longstanding provision, Medicare Part D is not permitted to cover drugs “when used for anorexia, weight loss, or weight gain.” Zepbound’s original 2023 FDA approval was for chronic weight management. Under that indication alone, Medicare cannot cover it.

Per an independent Medicare coverage analysis, “Medicare plans do not cover anti-obesity medications” when the drug is prescribed solely for weight loss.

The change: OSA approval opens Medicare coverage

In December 2024, the FDA approved Zepbound for a second indication — moderate-to-severe obstructive sleep apnea in adults with obesity. Per the same coverage analysis: “Medicare covers Zepbound for sleep apnea when it’s prescribed to treat moderate to severe obstructive sleep apnea (OSA).” The approval specifies: “Zepbound is only approved to treat sleep apnea in adults with obesity, which is defined as having a BMI of 30 or higher.”

That is the pathway. Medicare Part D can cover Zepbound when the prescription documents:

1. A diagnosis of moderate-to-severe obstructive sleep apnea.
2. A BMI of 30 or higher (obesity, per the FDA definition).
3. The prescribing indication as OSA, not weight loss.

What the beneficiary needs

• A diagnostic sleep study. OSA is diagnosed by a sleep study (polysomnography or a home sleep study). The study must document moderate-to-severe OSA (typically an apnea-hypopnea index of ≥15 events per hour).
• A BMI of 30 or higher. Documented in the medical record.
• A prescribing clinician who names OSA as the indication. Pharmacies and plans check the diagnosis code on the prescription. A prescription for “weight loss” or “obesity management” will be denied.
• Coverage from a Medicare Part D plan or a Medicare Advantage plan with prescription drug coverage. Not all plans cover Zepbound; check the plan’s formulary.

Cost-sharing

Zepbound is a specialty drug. For a Medicare Part D plan or an MA-PD plan that covers Zepbound for OSA:

• Tier placement. Typically Tier 4 or Tier 5 (specialty or non-preferred brand). Copayments and coinsurance are highest at these tiers.
• Deductible. The Part D deductible applies before coinsurance in most plans.
• Coinsurance during initial phase. Often 25-33 percent of the plan-negotiated price.
• Out-of-pocket cap. The Inflation Reduction Act’s $2,000 annual out-of-pocket cap on Part D drugs applies for 2026. Beneficiaries hit the cap and then pay zero for the rest of the year.

A manufacturer bridge program may reduce first-fill cost. Beneficiaries should check Lilly’s Zepbound Savings Program eligibility, though Medicare-enrolled beneficiaries have limited access to manufacturer copay cards due to anti-kickback regulations.

If the plan denies coverage

• Verify the diagnosis on the prescription. A rejection often traces to the prescriber writing “weight loss” or omitting the OSA diagnosis code.
• Ask the plan for the specific denial reason. Prior authorization, formulary exclusion, or non-coverage of the indication.
• File a formulary exception. If the plan does not have Zepbound on its formulary at all, a formulary exception request can be submitted.
• Consider the Part D appeal process. Denials can be appealed through the standard Part D redetermination and reconsideration process.

The broader Medicare determination appeal process — reconsideration → Administrative Law Judge hearing → Appeals Council → federal district court — applies in parallel for Part D coverage disputes.

What Medicare does not cover

• Zepbound prescribed for weight loss alone (even with high BMI).
• Zepbound for prediabetes without an FDA-approved indication.
• Non-FDA-approved uses (off-label).

When a patient advocate helps

• The prescription was denied and the OSA diagnosis is on record. An advocate can review the prescription and rejection reason, identify whether the prescriber needs to update the diagnosis code, and pursue formulary exceptions or appeals.
• The beneficiary has both diabetes and OSA. For diabetes, Ozempic or Mounjaro (same molecule as Zepbound, different brand) may be covered; the advocate can help navigate the drug and plan choice.
• The MA plan has a specific prior authorization requirement. Advocates familiar with the plan can expedite the paperwork.

Contact Baba Care if a Zepbound prescription has been denied and the underlying condition qualifies.

Frequently asked questions

Does Medicare cover Zepbound for weight loss? No. Medicare Part D cannot cover drugs used for anorexia, weight loss, or weight gain.

Does Medicare cover Zepbound for sleep apnea? Yes, since December 2024’s FDA approval, when the beneficiary has moderate-to-severe OSA and a BMI of 30 or higher.

Is Zepbound the same as Mounjaro? Same molecule (tirzepatide), different brands and indications. Mounjaro is approved for type 2 diabetes; Zepbound is approved for chronic weight management and, since December 2024, obstructive sleep apnea.

What if I have OSA but my BMI is below 30? The FDA approval requires BMI ≥30. Below that threshold, Zepbound is not FDA-approved for OSA and Medicare will not cover it under that indication.

How much does Zepbound cost without Medicare coverage? Cash price is approximately $1,000 or more per month, depending on the pharmacy and dose.

About Baba Care. Baba Care is a patient advocacy service supporting families navigating Medicare and complex care decisions.

Medical / financial disclaimer. This article is educational and does not constitute medical, financial, or legal advice.

Additional source references

• FDA · December 2024 approval of tirzepatide (Zepbound) for moderate-to-severe OSA
• Medicare Modernization Act · statutory Part D exclusion for anti-obesity drugs